Investors
Freemelt Holding AB (publ) publishes the Interim report for July – September, Q3 2024
Significant events July-September, Q3 2024
- Freemelt has entered a strategic partnership with 3DMZ (3D Makers Zone), Netherlands
- Freemelt has received an order from a North American customer for a feasibility study targeting
tungsten applications for fusion energy - Freemelt has become a member of the Georgia Tech Manufacturing 4.0 Consortium
- Freemelt has received an order from a North American defense company for a feasibility study
targeting tungsten applications for defense - Freemelt has received an order from Nuclear AMRC (Nuclear Advanced Manufacturing Research
Centre) for 3D printed tungsten parts for fusion energy - Freemelt has received an order for Freemelt ONE from The University of Birmingham
- Freemelt has received an order for Freemelt ONE from one of the world’s premier research institutes
- Freemelt has established an application center in North America with HAMR Industries LCC
Key figures July-September, Q3 2024
| KSEK | Jul-Sep | Jul-Sep | Full year |
| 2024 | 2023 | 2023 | |
| Net sales | 8 650 | 8 152 | 22 310 |
| Operating result | -18 157 | -17 696 | -84 024 |
| Result after fin. items | -17 972 | -17 485 | -82 854 |
| Balance sheet total | 242 684 | 270 883 | 254 686 |
| Equity ratio | 92% | 95% | 94% |
| Cash flow | -21 330 | -12 958 | 23 052 |
Freemelt CEO Daniel Gidlund comments:
“During the third quarter, we reached significant milestones on our path to commercialization. We successfully installed our first industrial eMELT machine, at WEAREAM in Italy. This installation marks our transition from R&D to industrial applications and is an important step towards serial production. WEAREAM is our first eMELT customer and is important for Freemelt in building trust with other potential industrial customers in Europe and the U.S., in industries such as defense, energy, and medical technology, with an interest in serial production via eMELT.
After the quarter, we secured an order from a global orthopedic implant OEM (Original Equipment Manufacturer) for a proof-of-concept on serial production capabilities using eMELT. This order is a major milestone for Freemelt and strengthens our position in the medical technology sector and represents our first major customer in the orthopedic implant industry, a sector with the highest adoption of additive manufacturing for serial production. Our WEAREAM installation together with the OEM order really shows our progress and the growing interest in our eMELT machine and our expanding role in critical industries.”
Freemelt will host a live webcast and Q&A on November 5, at 11:30 am CET. The webcast can be accessed via this link: https://www.finwire.tv/webcast/freemelt/q3-2024/. The recording will be available afterward.
Freemelt’s CEO Daniel Gidlund will be interviewed by Redeye analyst Anton Hoof on November 5 at 09:30 am CET. You can watch the interview by registering at this link:
https://www.redeye.se/company/freemelt
The full report is available as an attached PDF and at Freemelt’s website: Freemelt Financial Reports